ストックスクリーナーアプリを入手
5.31
5.37%
0.28
前日終値:
$5.03
開ける：
$5.01
24時間の取引高:
30,958
Relative Volume:
0.20
時価総額：
$6.26M
収益：
$12.99M
当期純損益:
$-27.45M
株価収益率:
-0.00298
EPS:
-1779.0561
ネットキャッシュフロー:
$-25.59M
1週間 パフォーマンス:
+23.83%
1か月 パフォーマンス:
+19.91%
6か月 パフォーマンス:
-81.25%
1年 パフォーマンス:
-98.47%
1日の値動き範囲:
$5.01
$5.4096
1週間の範囲:
$4.1801
$5.4096
52週間の値動き範囲:
$3.80
$486.00
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Compare APVO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
5.30 | 5.94M | 12.99M | -27.45M | -25.59M | -1,779.06 |
VRTX
Vertex Pharmaceuticals Inc
|
444.51 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.11 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
842.52 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
336.64 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.40 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-11-05 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-10-05 | 再開されました | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc (APVO) 最新ニュース
Risk On: Is Aptevo Therapeutics Inc impacted by rising ratesPortfolio Update Report & AI Driven Price Forecasts - baoquankhu1.vn
Aptevo Therapeutics (APVO) upgraded to buy: Here's why - MSN
Aug Chart Watch: What is Aptevo Therapeutics Incs valuation compared to sector2026 Reactions & Smart Money Movement Tracker - baoquankhu1.vn
Aug Swings: Is The Honest Company Inc stock risky to hold nowMarket Movement Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aptevo Therapeutics (APVO) Raised to Buy: Discover the Reasons - Bitget
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why - Yahoo Finance
Tech Rally: Is Aptevo Therapeutics Inc impacted by rising rates2026 Sector Review & Real-Time Chart Breakout Alerts - baoquankhu1.vn
APVO Forecast, Price Target & Analyst Ratings | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill
APVO Should I Buy - Intellectia AI
APVO Technical Analysis & Stock Price Forecast - Intellectia AI
Update Recap: Can Aptevo Therapeutics Inc sustain its profitabilityMarket Movers & Risk Managed Investment Signals - baoquankhu1.vn
Institution Moves: Will IBEX outperform during market ralliesWeekly Risk Summary & Smart Allocation Stock Tips - baoquankhu1.vn
Nasdaq Moves: What are Aptevo Therapeutics Incs recent SEC filings showing2026 Buyback Activity & Expert Curated Trade Setups - baoquankhu1.vn
Risk Report: Is Aptevo Therapeutics Inc impacted by rising rates2026 Price Targets & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate in Frontline AML Trial - citybuzz -
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment - NewMediaWire
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | Corporate - EQS News
User - The Chronicle-Journal
Aptevo Rises on AML Data—But Will It Hold? - Bitget
Aptevo Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
10-K - sec.gov
Aptevo Therapeutics 10-K: Net loss $25.97M, EPS $(87.27) - TradingView
Aptevo Therapeutics (NASDAQ: APVO) outlines bispecific cancer pipeline and AML data - Stock Titan
[8-K] Aptevo Therapeutics Inc. Reports Material Event - Stock Titan
APVO Achieves Significant Advances in Clinical Pipeline and Capi - GuruFocus
Aptevo Provides State of the Business Report and 2025 Financial Results - Bitget
Aptevo (APVO) Strengthens Financial Position for Future Operatio - GuruFocus
No CRS in 28 AML patients as Aptevo adds 3 CD3 drug candidates - Stock Titan
APVO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aptevo Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | AP81 | US03835L5049 - marketscreener.com
Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | APVO | US03835L4059 - marketscreener.com
Aptevo to Participate in March 2026 Conferences - ACCESS Newswire
Aptevo sends incoming CEO to Roth, spotlights trispecific drugs in Lisbon - Stock Titan
Hedge Fund Moves: Whats next for Aptevo Therapeutics Inc stock2026 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Aptevo Therapeutics implements 1-for-18 reverse stock split - MSN
Pharma News: Is GeoVax Labs Inc Equity Warrants ROE strong enough2026 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
Aptevo shares drop despite encouraging AML trial results - MSN
Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate With No CRS in Frontline AML, Promising Safety and Efficacy Data 1 - Minichart
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Aptevo Reports Promising Interim Data for AML Therapy - TipRanks
Aptevo Therapeutics: Mipletamig Shows 86% Clinical Benefit Rate with No CRS in Frontline AML - TradingView
Aptevo Therapeutics Inc Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine - marketscreener.com
Aptevo Therapeutics (APVO) reports 86% benefit, no CRS in mipletamig AML data - Stock Titan
Aptevo Therapeutics (APVO) Reveals Promising Results in AML Tria - GuruFocus
Aptevo Lists Lower on New Developments - Baystreet.ca
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aptevo Therapeutics stock tumbles despite positive trial data - Investing.com India
Aptevo Therapeutics stock tumbles despite positive trial data By Investing.com - Investing.com UK
Aptevo Therapeutics Inc (APVO) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
0.19%
大文字化:
|
ボリューム (24 時間):